利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.02 秒)

    Modulation of Hematopoietic Stem Cell Differentiation
    1.
    发明申请
    Modulation of Hematopoietic Stem Cell Differentiation 审中-公开
    造血干细胞分化调节

    公开(公告)号：US20150299712A1

    公开(公告)日：2015-10-22

    申请号：US14595078

    申请日：2015-01-12

    申请人： Christine Victoria Ichim ,  Tom Ichim

    发明人： Christine Victoria Ichim ,  Tom Ichim

    IPC分类号： C12N15/113

    CPC分类号： C12N15/1138 ,  A61K31/7105 ,  A61K31/713 ,  C12N2310/11 ,  C12N2310/531 ,  C12N2320/30 ,  G01N33/57426 ,  G01N33/6875 ,  G01N2333/70567 ,  G01N2800/22

    摘要： The invention provides means of manipulating hematopoietic stem cell differentiation by modulation of levels of NR2F6 (EAR2). Provided are compositions of matter, protocols and methods of use by which inhibiting expression of NR2F6 or activity thereof promotes differentiation of selective hematopoietic lineages, or conversely overexpression of NR2F6 or activity thereof inhibits differentiation. In one embodiment inhibition of differentiation is performed in other cell lineages besides hematopoietic.

    摘要翻译： 本发明提供了通过调节NR2F6（EAR2）水平来操纵造血干细胞分化的方法。 提供了抑制NR2F6的表达或其活性促进选择性造血谱系分化的物质，方案和使用方法的组合物，或者NR2F6的过度表达或其活性抑制分化。 在一个实施方案中，在除造血之外的其他细胞谱系中进行分化的抑制。

    Treatment of Myelodysplastic Syndrome by Inhibition of NR2F6
    3.
    发明申请
    Treatment of Myelodysplastic Syndrome by Inhibition of NR2F6 审中-公开
    通过抑制NR2F6治疗骨髓增生异常综合征

    公开(公告)号：US20150203846A1

    公开(公告)日：2015-07-23

    申请号：US14572574

    申请日：2014-12-16

    申请人： Christine Victoria Ichim

    发明人： Christine Victoria Ichim

    IPC分类号： C12N15/113 ,  A61K45/06 ,  A61K9/127

    CPC分类号： C12N15/113 ,  A61K9/127 ,  A61K31/7105 ,  A61K31/713 ,  A61K45/06 ,  C12N2310/11 ,  C12N2310/14 ,  G01N33/57426 ,  G01N33/6875 ,  G01N2333/70567 ,  G01N2800/22

    摘要： Methods, compositions, and treatment protocols are provided in the current invention for the treatment of myelodysplastic syndrome (MDS) through the inhibition of NR2F6 gene expression or activity of protein. In one embodiment silencing, or substantial inhibition of NR2F6 expression is achieved through induction of RNA interference in cells associated with development of MDS. Induction of differentiation or stimulation of apoptosis as a result of NR2F6 inhibition may be used to reduce the state of MDS, and/or in other embodiments to inhibit or revert progression to leukemic states.

    摘要翻译： 本发明提供了通过抑制NR2F6基因表达或蛋白质活性来治疗骨髓增生异常综合征（MDS）的方法，组合物和治疗方案。 在一个实施方案中，通过诱导与MDS发展相关的细胞中的RNA干扰来实现沉默，或实质上抑制NR2F6表达。 由于NR2F6抑制，诱导分化或刺激凋亡可以用于降低MDS的状态，和/或在其它实施方案中抑制或恢复进展为白血病状态。